Strategies To Mitigate Common Pitfalls In Early Drug Development

Thousands of drug candidates are abandoned annually due to solubility and bioavailability issues, but advanced formulation technologies can profoundly impact how a drug compound is processed in the body and improve the fate of many of these candidates, improving pharmacokinetic profiles and pharmacodynamic responses. Two Catalent experts discuss the ways companies can address issues with low bioavailability, and the benefits of enlisting an experienced drug development partner.

Featured Experts:
Jan Neelissen, Ph.D., Scientific Advisor, Science & Technology, Catalent
Stephen Tindal, Director, Science & Technology, Catalent